These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36436121)

  • 1. Effect of long-acting injectable antipsychotics on 1-year hospitalization in bipolar disorder: a mirror-image study.
    Bartoli F; Callovini T; Cavaleri D; Crocamo C; Riboldi I; Aguglia A; De Fazio P; Martinotti G; D'Agostino A; Ostuzzi G; Barbui C; Carrà G;
    Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1579-1586. PubMed ID: 36436121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of long-acting injectable antipsychotics on emergency department visits and hospital admissions in people with bipolar disorder: A retrospective mirror-image analysis from the Northern Milan Area Cohort (NOMIAC) study.
    Bartoli F; Bachi B; Calabrese A; Cioni RM; Guzzi P; Nasti C; Palpella D; Barbieri FF; Limonta S; Crocamo C; Carrà G
    J Affect Disord; 2022 Dec; 318():88-93. PubMed ID: 36058358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
    Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
    J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.
    Nielsen J; Jensen SO; Friis RB; Valentin JB; Correll CU
    Schizophr Bull; 2015 May; 41(3):627-36. PubMed ID: 25180312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-acting injectable antipsychotics for the treatment of bipolar disorder: evidence from mirror-image studies.
    Bartoli F; Cavaleri D; Nasti C; Palpella D; Guzzi P; Riboldi I; Crocamo C; Pappa S; Carrà G
    Ther Adv Psychopharmacol; 2023; 13():20451253231163682. PubMed ID: 36994116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-label long acting injectable antipsychotics in real-world clinical practice: a cross-sectional analysis of prescriptive patterns from the STAR Network DEPOT study.
    D'Agostino A; Aguglia A; Barbui C; Bartoli F; Carrà G; Cavallotti S; Chirico M; Ostinelli EG; Zangani C; Martinotti G; Ostuzzi G;
    BMC Psychiatry; 2022 Jun; 22(1):442. PubMed ID: 35773631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
    Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
    J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to rehospitalization in patients with bipolar mania discharged on long-acting injectable or oral antipsychotics.
    Lin CH; Chan HY; Hsu CC; Chen FC
    J Affect Disord; 2021 Jan; 279():292-298. PubMed ID: 33096327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review.
    Pacchiarotti I; Tiihonen J; Kotzalidis GD; Verdolini N; Murru A; Goikolea JM; Valentí M; Aedo A; Vieta E
    Eur Neuropsychopharmacol; 2019 Apr; 29(4):457-470. PubMed ID: 30770235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world effectiveness of long-acting injectable vs. oral antipsychotics in patients with bipolar I disorder: a 1-year retrospective observational study.
    Korkmaz ŞA; Gürler S
    Curr Med Res Opin; 2024 May; 40(5):855-861. PubMed ID: 38557295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-acting second-generation injectable antipsychotics for the maintenance treatment of bipolar disorder: a narrative review.
    Belge JB; Sabbe BGCC
    Expert Opin Pharmacother; 2024 Feb; 25(3):295-299. PubMed ID: 38465894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of long acting injectable antipsychotics on course and hospitalizations in bipolar disorder - a naturalistic mirror image study.
    Yıldızhan E; Uzun E; Tomruk NB
    Nord J Psychiatry; 2022 Jan; 76(1):37-43. PubMed ID: 34124986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of initiating long-acting injectable antipsychotics on hospitalization in patients with bipolar I disorder.
    Yan T; Greene M; Chang E; Touya M; Broder MS
    J Comp Eff Res; 2018 Nov; 7(11):1083-1093. PubMed ID: 30129771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.
    Kishimoto T; Nitta M; Borenstein M; Kane JM; Correll CU
    J Clin Psychiatry; 2013 Oct; 74(10):957-65. PubMed ID: 24229745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. All-cause hospitalization and associated costs in patients with schizophrenia or bipolar disorder initiating long-acting injectable antipsychotics.
    Yan T; Greene M; Chang E; Hartry A; Touya M; Broder MS
    Curr Med Res Opin; 2018 Jan; 34(1):41-47. PubMed ID: 29057674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis.
    Carswell C; Wheeler A; Vanderpyl J; Robinson E
    Clin Drug Investig; 2010; 30(11):777-87. PubMed ID: 20712387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".
    Jackson JW; Fulchino L; Rogers J; Mogun H; Polinski J; Henderson DC; Schneeweiss S; Fischer MA
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):95-104. PubMed ID: 29168261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.
    Kishimoto T; Robenzadeh A; Leucht C; Leucht S; Watanabe K; Mimura M; Borenstein M; Kane JM; Correll CU
    Schizophr Bull; 2014 Jan; 40(1):192-213. PubMed ID: 23256986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical determinants, patterns and outcomes of antipsychotic medication prescribing in the treatment of schizophrenia and schizoaffective disorder: A naturalistic cohort study.
    Groenendaal E; Lynch S; Dornbush R; Klepacz L; Ferrando S
    J Psychiatr Res; 2023 Feb; 158():273-280. PubMed ID: 36623361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.